logo
  

HCP Q4 Adj. FFO Tops View - Quick Facts

HCP Inc. (HCP) reported that its fourth-quarter Funds From Operations or FFO applicable to common shares declined to $328.2 million or $0.70 per share, from $349.3 million or $0.76 per share in the previous year.

But, adjusted FFO per share rose to $0.79 down from $0.76 last year. Analysts polled by Thomson Reuters expected the company to report earnings of $0.77 per share. Analysts' estimates typically exclude special items.

Net income applicable to common shares for the latest fourth-quarter declined to $196.1 million or $0.43 per share from the previous year's $292.6 million or $0.64 per share.

Total revenues for the quarter grew to $603.53 million from $530.30 million in the previous year, while four analysts had a consensus revenue estimate of $584.82 million for the quarter.

For full year 2015, the company expects FFO per share to be in the range of $3.14 to $3.20, FFO as adjusted per share to range between $3.15 and $3.21, Funds Available for Distribution or FAD per share in the range of $2.73 to $2.79 and earnings per share of $1.98 to $2.04. Analysts expect annual earnings of $3.18 per share.

On January 29, 2015, our Board of Directors declared a quarterly cash dividend of $0.565 per common share. The dividend will be paid on February 24, 2015 to stockholders of record as of the close of business on February 9, 2015.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT